<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140591</url>
  </required_header>
  <id_info>
    <org_study_id>V106C-137</org_study_id>
    <nct_id>NCT04140591</nct_id>
  </id_info>
  <brief_title>Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis</brief_title>
  <acronym>PU</acronym>
  <official_title>Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis: a Randomized Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton pump inhibitor plus propranolol versus proton pump inhibitor alone on peptic ulcer&#xD;
      healing in patients with liver cirrhosis: a randomized trail&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal hypertension is responsible for the development of portosystemic collaterals. The&#xD;
      hemodynamic alternations may result in mucosal and vascular changes along gastrointestinal&#xD;
      (GI) tract as well. According to several epidemiological studies, cirrhotic patients are at a&#xD;
      higher risk of developing peptic ulcers, delayed healing, and a higher frequency of ulcer&#xD;
      recurrence. The death rate from peptic ulcer disease in cirrhotic patients has been reported&#xD;
      to be five times higher than that of the general population. The exact mechanism remains&#xD;
      incompletely understood, but may be related to impaired mucosal defense mechanisms.&#xD;
      Aggressive factors such as Helicobacter pylori and gastric acid may not be the predominant&#xD;
      etiology in such circumstances. Sarfeh et al. found gastric mucosa of portal hypertensive&#xD;
      rats, compared with that of controls, has distinctive functional and histologic abnormalities&#xD;
      that can explain its increased susceptibility to erosive injury. Auroux et al. found&#xD;
      gastroduodenal ulcer was independently associated only with the severity of the hypertensive&#xD;
      gastropathy in cirrhotics. Chen et al. found portal hypertension with a hepatic venous&#xD;
      pressure gradient &gt; 12 mmHg may be an important factor contributing to the increased&#xD;
      prevalence of gastric ulcer observed in patients with liver cirrhosis. Thereby, we presumed&#xD;
      that clinically significant portal hypertension may play a role in development of peptic&#xD;
      ulcer in cirrhotic patients. Lebrec et al. elucidated non-selective beta-blocker (NSBB) could&#xD;
      significantly decrease portal pressure and lower the risk of GI bleeding in patients with&#xD;
      cirrhosis. Kitano et al. found portal hypotensive treatment with NSBB, reduces&#xD;
      ethanol-induced gastric mucosal damage in portal hypertensive rats and improves endoscopic&#xD;
      signs of portal hypertensive gastropathy in cirrhosis patients. We designed a 2-year&#xD;
      randomized trial to evaluate the effectiveness of proton pump inhibitor with or without&#xD;
      propranolol on ulcer healing and the incidence of ulcer bleeding in patients with cirrhosis&#xD;
      and peptic ulcers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1. Most patients with liver cirrhosis already use PPI and NSBB 2. 90 % Peptic ulcer size is&#xD;
    smaller than 5cm&#xD;
  </why_stopped>
  <start_date type="Actual">December 26, 2016</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing of peptic ulcer</measure>
    <time_frame>2 months</time_frame>
    <description>if propranolol can help cure peptic ulcer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding rate of peptic ulcer</measure>
    <time_frame>2 months</time_frame>
    <description>if propranolol can help decrease the rate of ulcer bleeding</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Proton-pump inhibitor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PPI: Pariet EC 20 mg/QDAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol+Proton-pump inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol:&#xD;
Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate&gt;55 or systemic blood pressure&gt;90mmHg)&#xD;
PPI: Pariet EC 20 mg/QDAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proton-pump inhibitor</intervention_name>
    <description>PPI: Pariet EC 20mg/QDAC</description>
    <arm_group_label>Proton-pump inhibitor</arm_group_label>
    <other_name>Pariet EC</other_name>
    <other_name>PPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol+Proton-pump inhibitor</intervention_name>
    <description>Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate&gt;55 or systemic blood pressure &gt;90mmHg) PPI: Pariet EC 20mg/QDAC</description>
    <arm_group_label>Propranolol+Proton-pump inhibitor</arm_group_label>
    <other_name>Inderal</other_name>
    <other_name>Cardolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 20 and 85 years old&#xD;
&#xD;
          -  Liver cirrhosis associated with esophageal varices or gastric varices&#xD;
&#xD;
          -  Gastric ulcer or duodenal ulcer ,size bigger or egual than 0.5 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute bleeding&#xD;
&#xD;
          -  Steroid or NSAID user&#xD;
&#xD;
          -  Pregnancy, or the patients with other terminal illness (such as other terminal&#xD;
             cancers, heart failure, renal failure...)&#xD;
&#xD;
          -  Propranolol contraindications (such as atrioventricular block, heart failure, chronic&#xD;
             obstructive pulmonary disease, asthma, poorly controlled diabetes, severe peripheral&#xD;
             arterial disease...)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Chih mchou@vghtpe.gov.tw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institutional Review Board, Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital, Taiwan</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>The Division of Gastroenterology &amp; Hepatology</investigator_title>
  </responsible_party>
  <keyword>Portal hypertension</keyword>
  <keyword>Peptic ulcer</keyword>
  <keyword>Non-selective beta-blocker</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

